NOS3 and endothelial dysfunction: Treatment of human endothelial cells with 1,25(OH)2D increased the expression of NO through activation of eNOS [88], and VDR mutant mice have a lower bioavailability of NO due to reduced eNOS expression in their vasculature, leading to endothelial dysfunction and increased arterial stiffness [87].